

Richard Choo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7155685/publications.pdf>

Version: 2024-02-01

50
papers

1,454
citations

361045

20
h-index

315357

38
g-index

50
all docs

50
docs citations

50
times ranked

2183
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase II trial of hypofractionated radiation therapy over five treatments for prostate cancer with high-risk features after radical prostatectomy: MC1754.. Journal of Clinical Oncology, 2022, 40, 248-248.	0.8	0
2	Approaching automated applicator digitization from a new angle: Using sagittal images to improve deep learning accuracy and robustness in high-dose-rate prostate brachytherapy. Brachytherapy, 2022, 21, 520-531.	0.2	4
3	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. JAMA Network Open, 2021, 4, e2115312.	2.8	12
4	Predictors of Locoregional Recurrence and Delineation of Adjuvant Radiation Therapy Fields for Patients With Upper Tract Urothelial Carcinoma Receiving Nephroureterectomy. Practical Radiation Oncology, 2021, 11, e468-e476.	1.1	2
5	Proton Therapy of Prostate and Pelvic Lymph Nodes for High Risk Prostate Cancer: Acute Toxicity. International Journal of Particle Therapy, 2021, 8, 41-50.	0.9	5
6	Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial. Radiotherapy and Oncology, 2021, 163, 21-31.	0.3	7
7	Assessing concordance between patient-reported and investigator-reported CTCAE after proton beam therapy for prostate cancer. Clinical and Translational Radiation Oncology, 2021, 31, 34-41.	0.9	4
8	Comparing bowel and urinary domains of patient-reported quality of life at the end of and 3 months post radiotherapy between intensity-modulated radiotherapy and proton beam therapy for clinically localized prostate cancer. Cancer Medicine, 2020, 9, 7925-7934.	1.3	6
9	Outcomes and Profiles of Older Patients Receiving Definitive Radiation Therapy for Muscle-Invasive Bladder Cancer at a Tertiary Medical Center. Practical Radiation Oncology, 2020, 10, e378-e387.	1.1	1
10	Is there any benefit in adding postoperative adjuvant concurrent radiotherapy and chemotherapy for penile cancer with regional lymph node metastasis?. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 474-481.	3.9	9
11	The impact of genetic mutations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.. Journal of Clinical Oncology, 2020, 38, e17587-e17587.	0.8	0
12	Acute patient-reported toxicities after proton therapy or intensity-modulated radiotherapy for prostate cancer.. Journal of Clinical Oncology, 2020, 38, 305-305.	0.8	0
13	Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases. Advances in Radiation Oncology, 2019, 4, 314-322.	0.6	9
14	IMPT versus VMAT for Pelvic Nodal Irradiation in Prostate Cancer: A Dosimetric Comparison. International Journal of Particle Therapy, 2019, 5, 11-23.	0.9	16
15	Low dose rate prostate brachytherapy. Translational Andrology and Urology, 2018, 7, 341-356.	0.6	30
16	Increased utilization of external beam radiotherapy relative to cystectomy for localized, muscle-invasive bladder cancer: a SEER analysis. Bladder, 2018, 5, e34.	0.6	2
17	Proton Therapy for Stage IIA-B Seminoma: A New Standard of Care for Treating Retroperitoneal Nodes. International Journal of Particle Therapy, 2018, 5, 50-57.	0.9	6
18	Brachytherapy in the Management of Prostate Cancer. Surgical Oncology Clinics of North America, 2017, 26, 491-513.	0.6	17

#	ARTICLE	IF	CITATIONS
19	Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 526-535.	0.4	35
20	Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease. <i>European Urology</i> , 2017, 71, 340-348.	0.9	51
21	Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. <i>BMJ</i> , The, 2016, 352, i851.	3.0	180
22	Establishment of practice standards in nomenclature and prescription to enable construction of software and databases for knowledge-based practice review. <i>Practical Radiation Oncology</i> , 2016, 6, e117-e126.	1.1	26
23	Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 70, 21-30.	0.9	222
24	Neuroendocrine Differentiation in Prostate Cancer: A Mechanism of Radioresistance and Treatment Failure. <i>Frontiers in Oncology</i> , 2015, 5, 90.	1.3	116
25	Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer. <i>Radiation Oncology</i> , 2015, 10, 95.	1.2	4
26	Excellent long-term disease control with modern radiotherapy techniques for stage I testicular seminomaâ€”The Mayo Clinic experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 24.e1-24.e6.	0.8	12
27	Outcomes in a Multi-institutional Cohort of Patients Treated With Intraoperative Radiation Therapy for Advanced or Recurrent Renal Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 618-623.	0.4	28
28	Late gastrointestinal morbidity in patients with stage Iâ€”II testicular seminoma treated with radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 496-500.	0.8	9
29	Randomized, Double-Blinded, Placebo-Controlled, Trial of Risedronate for the Prevention of Bone Mineral Density Loss in Nonmetastatic Prostate Cancer Patients Receiving Radiation Therapy Plus Androgen Deprivation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1239-1245.	0.4	48
30	Long-term outcomes of radiotherapy for stage II testicular seminomaâ€”the Mayo Clinic experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1832-1838.	0.8	20
31	Can radiotherapy be a viable salvage treatment option for the relapsed seminoma confined to the infra-diaphragm region recurring after primary chemotherapy for bulky stage II seminoma?. <i>Canadian Urological Association Journal</i> , 2013, 4, 137.	0.3	5
32	Recommendations for CTV margins in radiotherapy planning for non melanoma skin cancer. <i>Radiation Therapy and Oncology</i> , 2012, 104, 263-266.	0.3	31
33	Prospective survey of sexual function among patients with clinically localized prostate cancer referred for definitive radiotherapy and the impact of radiotherapy on sexual function. <i>Supportive Care in Cancer</i> , 2010, 18, 715-722.	1.0	23
34	Salvage Radiotherapy for Patients with PSA Relapse Following Radical Prostatectomy: Issues and Challenges. <i>Cancer Research and Treatment</i> , 2010, 42, 1.	1.3	22
35	Prospective Study Evaluating Postoperative Radiotherapy Plus 2-Year Androgen Suppression for Postâ€”Radical Prostatectomy Patients With Pathologic T3 Disease and/or Positive Surgical Margins. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 407-412.	0.4	16
36	Efficacy of Salvage Radiotherapy Plus 2-Year Androgen Suppression for Postradical Prostatectomy Patients With PSA Relapse. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 983-989.	0.4	36

#	ARTICLE	IF	CITATIONS
37	Analysis of Gastrointestinal and Genitourinary Morbidity of Postoperative Radiotherapy for Pathologic T3 Disease or Positive Surgical Margins After Radical Prostatectomy Using National Cancer Institute Expanded Common Toxicity Criteria. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 989-995.	0.4	15
38	Prospective Assessment of Gastrointestinal and Genitourinary Toxicity of Salvage Radiotherapy for Patients With Prostate-Specific Antigen Relapse or Local Recurrence After Radical Prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 792-798.	0.4	32
39	Prospective Evaluation of Quality of Life in Prostate Cancer Patients Receiving Combined Treatment of Postoperative Radiotherapy Plus Androgen Suppression for PT3 or Positive Resection Margin after Radical Prostatectomy. <i>European Urology</i> , 2007, 52, 1645-1652.	0.9	11
40	Two different perspectives in the management of pT3 and/or margin-positive prostate cancer after radical prostatectomy. <i>BJU International</i> , 2006, 98, 773-776.	1.3	5
41	Effect of combined treatment with salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 78-83.	0.4	20
42	Long-term outcome of postorchietomy surveillance for Stage I testicular seminoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 736-740.	0.4	83
43	Individualized planning target volumes for intrafraction motion during hypofractionated intensity-modulated radiotherapy boost for prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 418-425.	0.4	77
44	What is the microscopic tumor extent beyond clinically delineated gross tumor boundary in nonmelanoma skin cancers?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 1096-1099.	0.4	19
45	Limited efficacy of salvage radiotherapy for biopsy confirmed or clinically palpable local recurrence of prostate carcinoma after surgery. <i>Radiotherapy and Oncology</i> , 2005, 74, 163-167.	0.3	16
46	How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?. <i>Canadian Journal of Urology</i> , 2005, 12, 2547-52.	0.0	23
47	Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 674-680.	0.4	63
48	(IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 269-276.	0.4	58
49	Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States. <i>Canadian Journal of Urology</i> , 2002, 9, 1479-85.	0.0	18
50	Can radiotherapy salvage isolated local recurrence following radical prostatectomy?. <i>Canadian Journal of Urology</i> , 1997, 4, 395-399.	0.0	0